Key result
Hypertension plus COVID-19 linked to ~26% higher arginase activity versus healthy controls.
Why the study?
The level of nitric oxide production and arginase activity in patients with arterial hypertension and type II diabetes mellitus during SARS-CoV-2 infection was not well characterized.
Cross-Sectional (n=111)
No
Effect estimate: 26% increase
Absolute Event Rate: 10.33% vs 7.69%
p-value: p=<0.05
COVID-19 and diabetes mellitus significantly alter nitric oxide metabolism and arginase activity in patients with arterial hypertension, highlighting potential pharmacological targets.
Altered NO/arginase activity in hypertensive COVID-19 patients with diabetes is hypothesis-generating; leaves open any role in risk stratification or therapy.
The aim of this study was to assess the level of nitric oxide production and arginase activity in patients with arterial hypertension and type II diabetes mellitus during infection with SARS-CoV-2. The study groups included patients with arterial hypertension, patients with arterial hypertension combined with a severe course of COVID-19 and patients who, in addition to arterial hypertension and COVID-19, were suffering from type II diabetes mellitus. The volunteers without any clinical signs of diseases and normal blood pressure formed the control group. It has been established that arterial hypertension, combined with COVID-19 occurs along with reduced L-arginine, nitric oxide, superoxide dismutase activity and increased arginase activity. At the same time, the presence of arterial hypertension in patients with diabetes and coronavirus disease is accompanied by a decline in the content of L-arginine and arginase activity. Our study’s results may help scientists find new pharmacological targets in the future treatment of coronavirus disease and comorbid disorders.
No takes yet. Share an insight, caveat, or question.
Sklyarova et al. (2022) conducted a cross-sectional in Arterial Hypertension, COVID-19, Type II Diabetes Mellitus (n=111). COVID-19 and Type II Diabetes Mellitus vs. Healthy controls and patients with arterial hypertension only was evaluated on Arginase activity (μmol of urea/min×mg of protein) (26% increase, p=<0.05). Arterial hypertension combined with COVID-19 was associated with a 26% increase in arginase activity and reduced L-arginine levels compared to healthy controls, while the addition of diabetes mellitus was accompanied by a decline in arginase activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: